Get the Stockscreener App
14.14
4.12%
0.56
After Hours:
14.50
0.36
+2.55%
Zymeworks Inc. stock is traded at $14.14, with a volume of 1.53M.
It is up +4.12% in the last 24 hours and down -2.82% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$13.58
Open:
$13.24
24h Volume:
1.53M
Relative Volume:
3.20
Market Cap:
$973.93M
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
5.05
EPS:
2.8
Net Cash Flow:
$-96.01M
1W Performance:
+12.40%
1M Performance:
-2.82%
6M Performance:
+68.13%
1Y Performance:
+52.54%
1-Day Range:
$13.11
$14.15
1-Week Range:
$12.48
$14.15
52-Week Range:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.14 | 973.93M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Zymeworks (NYSE:ZYME) Shares Down 2.4%Here's Why - MarketBeat
Y Intercept Hong Kong Ltd Has $147,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Zymeworks (NYSE:ZYME) Stock Price Up 4.3% Following Analyst Upgrade - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock Price - MarketBeat
Zymeworks Stock: Prime Time Ziihera, Early-Stage Pipeline Ahead Of Schedule (NASDAQ:ZYME) - Seeking Alpha
Wellington Management Group LLP Has $3.05 Million Position in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
JP Morgan Upgrades Zymeworks (ZYME) - MSN
Zymeworks (NYSE:ZYME) Shares Gap UpHere's Why - MarketBeat
Zymeworks (NYSE:ZYME) Upgraded at JPMorgan Chase & Co. - MarketBeat
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases - The Manila Times
Zymeworks speeds up cancer drug development timeline - Investing.com
Zymeworks Hosts R&D Day Highlighting Continued Clinical - GlobeNewswire
Zymeworks Accelerates Cancer Drug Pipeline, Unveils Breakthrough Autoimmune Program 18 Months Ahead of Schedule - StockTitan
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Zymeworks adjusts non-employee director pay By Investing.com - Investing.com Canada
Zymeworks adjusts non-employee director pay - Investing.com
Jacobs Levy Equity Management Inc. Sells 129,088 Shares of Zymeworks Inc. (NYSE:ZYME) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $19.13 Million Holdings in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (NYSE:ZYME) is Redmile Group LLC's 6th Largest Position - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vestal Point Capital LP Boosts Stake in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Bloom Burton Estimates Zymeworks FY2024 Earnings - MarketBeat
HC Wainwright Reaffirms Neutral Rating for Zymeworks (NYSE:ZYME) - MarketBeat
In-Depth Examination Of 9 Analyst Recommendations For Zymeworks - Benzinga
FDA approves cancer drug developed by B.C.'s Zymeworks - Head Topics
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework - Benzinga
Zymeworks to Showcase Innovations at Investor Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Zymeworks to Present at Major Healthcare Conferences, Announces R&D Day for Pipeline Updates | ZYME Stock News - StockTitan
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for - GlobeNewswire
Zymeworks' Ziihera Wins FDA Approval: First Dual HER2 Cancer Drug Shows 52% Response Rate | ZYME Stock News - StockTitan
Leerink Partners Upgrades Zymeworks (ZYME) - MSN
Redmile Group, LLC Adjusts Stake in Zymeworks Inc - GuruFocus.com
Zymeworks stock soars to 52-week high, hits $17.29 By Investing.com - Investing.com Australia
Zymeworks stock soars to 52-week high, hits $17.29 - Investing.com India
Zymeworks (NYSE:ZYME) Stock Rating Upgraded by Leerink Partners - Defense World
FY2024 EPS Estimates for Zymeworks Lifted by Leerink Partnrs - MarketBeat
Analysts Update Their Estimates For Zymeworks BC Inc - Stocks Register
Q4 Earnings Estimate for Zymeworks Issued By Leerink Partnrs - Defense World
Zymeworks (NYSE:ZYME) Raised to Strong-Buy at Leerink Partnrs - Defense World
Leerink Partnrs Forecasts Zymeworks' Q4 Earnings (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking - Simply Wall St
Zymeworks (NYSE:ZYME) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink lifts Zymeworks stock target on pipeline progress By Investing.com - Investing.com Nigeria
Leerink lifts Zymeworks stock target on pipeline progress - Investing.com
Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours - Clinical Trials Arena
Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $18.00 - Defense World
Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire
Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):